ALK and prostate cancer: The ALK fusion-positive cohort included 8 distinct tumor/histological subtypes, the most common of which were colorectal cancer (n = 9; 40.9%), sarcoma (n = 3; 13.6%), and prostate cancer (n = 3; 13.6%) (Figure 2).